Dermatology

The literature on topical steroid withdrawal syndrome is scant, Glick says; we're learning more about it, but we need more research to help our patients.

RAD 2025: Peter Lio, MD, discussed the benefits of disease-specific meetings, the evolving AD landscape, and why continuity across sessions enhances clinician education.

RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.

Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.

At RAD 2025, pediatric dermatologist Elizabeth Swanson, MD, discussed the value of focused AD education and anticipated label expansions for several treatments.

At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.

RAD 2025: Chovatiya toplines shifts in dosing strategies for topical, oral, and injectable AD therapy observed in both clinical trials and clinical practice.

RAD 2025. Peter Lio, MD, shares details from his presentation on shared decision making when treating children with atopic dermatitis.

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

RAD 2025: Chovatiya spoke at RAD about the need to better understand how treatments for AD are being used in the real world, after symptoms subside and skin signs clear.